Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Edward J, Gane"'
Autor:
Man-Fung Yuen, Scott Fung, Xiaoli Ma, Tuan T. Nguyen, Tarek Hassanein, Hie-Won Hann, Magdy Elkhashab, Ronald G. Nahass, James S. Park, Ira M. Jacobson, Walid S. Ayoub, Steven-Huy Han, Edward J. Gane, Katie Zomorodi, Ran Yan, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Frank Weilert, Alnoor Ramji, Michael Bennett, Natarajan Ravendhran, Sing Chan, Douglas T. Dieterich, Paul Yien Kwo, Eugene R. Schiff, Ho S. Bae, Jacob Lalezari, Kosh Agarwal, Mark S. Sulkowski
Publikováno v:
JHEP Reports, Vol 6, Iss 4, Pp 100999- (2024)
Background & Aims: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In this long-term extension study, patie
Externí odkaz:
https://doaj.org/article/79c1f480374a43d2b19433829b3f31b0
Autor:
Man‐Fung Yuen, Elina Berliba, Wattana Sukeepaisarnjaroen, Sang Hoon Ahn, Tawesak Tanwandee, Young‐Suk Lim, Yoon Jun Kim, Kittiyod Poovorawan, Pisit Tangkijvanich, Christian Schwabe, Timothy Eley, Joanne Brown, Amy C. H. Lee, Emily P. Thi, Bhavna Paratala, Nagraj Mani, Michael J. Sofia, Gaston Picchio, Karen D. Sims, Edward J. Gane
Publikováno v:
Hepatology Communications, Vol 6, Iss 12, Pp 3457-3472 (2022)
Abstract AB‐506 is a potent, pan‐genotypic small molecule capsid inhibitor that inhibits hepatitis B virus (HBV) pregenomic RNA encapsidation. We assessed the safety, pharmacokinetics, and antiviral activity of AB‐506 in two randomized, double
Externí odkaz:
https://doaj.org/article/6ea02a9ddc574a2288f20604466e8868
Autor:
Wai Kay Seto, Ting-Tsung Chang, Abhijit Chowdhry, Chi-Yi Chen, Mustafa Kemal Celen, Xiaoli Ma, Mang Ma, Ajay Duseja, Ki Tae Yoon, Wan Cheng Chow, Leland Yee, Gregor Weber, Ms Jin Youn, John F. Flaherty, Anuj Gaggar, Bing Gao, Gregory Camus, Eric Bassetti, Jae Seok Hwang, Tetshuro Inokuma, Young- Suk Lin, Edward J. Gane
Publikováno v:
Annals of Hepatology, Vol 28, Iss , Pp 100905- (2023)
Introduction and Objectives: Tenofovir Alafenamide (TAF) is a preferred treatment in the most recent EASL and AASLD HBV Guidelines, especially in patients with risk factors for TDF-associated renal and bone effects. In 2 identically-designed double-b
Externí odkaz:
https://doaj.org/article/ff618283cb6f44cfa2d42ed8f0d2ea63
Autor:
Edward J. Gane, P. Rod Dunbar, Anna E. Brooks, Fangqiu Zhang, Diana Chen, Jeffrey J. Wallin, Nicholas van Buuren, Priyanka Arora, Simon P. Fletcher, Susanna K. Tan, Jenny C. Yang, Anuj Gaggar, Shyamasundaran Kottilil, Lydia Tang
Publikováno v:
Journal of Hepatology. 78:513-523
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7755c6a1096a5a1381f3283dec393bf7
https://doi.org/10.1016/j.jhep.2022.09.027
https://doi.org/10.1016/j.jhep.2022.09.027
Autor:
Calvin Q Pan, Ting-Tsung Chang, Si Hyun Bae, Maurizia Brunetto, Wai-Kay Seto, Carla S Coffin, Susanna K Tan, Shuyuan Mo, John F Flaherty, Anuj Gaggar, Mindie H Nguyen, Mustafa Kemal Çelen, Alexander Thompson, Edward J Gane
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251552 (2021)
Background/purposeUse of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for teno
Externí odkaz:
https://doaj.org/article/7c9eee4d9c294440a763ea36e111adf4
Autor:
Ohad Etzion, Saeed Hamid, Yoav Lurie, Edward J. Gane, David Yardeni, Sarah Duehren, Nimrah Bader, Anat Nevo-Shor, Saleh Muhammad Channa, Scott J. Cotler, Minaz Mawani, Om Parkash, Harel Dahari, Ingrid Choong, Jeffrey S. Glenn
Publikováno v:
Hepatology. 77:2093-2103
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d02eebbcf7eccc46549ca6389fa7e1d9
https://doi.org/10.1097/hep.0000000000000309
https://doi.org/10.1097/hep.0000000000000309
Autor:
Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan T. Nguyen, Eugene R. Schiff, Hie-Won L. Hann, Douglas T. Dieterich, Ronald G. Nahass, James S. Park, Sing Chan, Steven-Huy B. Han, Edward J. Gane, Michael Bennett, Katia Alves, Marc Evanchik, Ran Yan, Qi Huang, Uri Lopatin, Richard Colonno, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Ira M. Jacobson, Walid S. Ayoub, Frank Weilert, Natarajan Ravendhran, Alnoor Ramji, Paul Yien Kwo, Magdy Elkhashab, Tarek Hassanein, Ho S. Bae, Jacob P. Lalezari, Scott K. Fung, Mark S. Sulkowski
Publikováno v:
Journal of Hepatology. 77:642-652
HBV nucleos(t)ide reverse transcriptase inhibitors (NrtIs) do not completely suppress HBV replication. Previous reports indicate persistent viremia during NrtI treatment despite HBV DNA being undetectable. HBV core inhibitors may enhance viral suppre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd7a77f9cac5a69525b2790e5ecdf2d1
https://doi.org/10.1016/j.jhep.2022.04.005
https://doi.org/10.1016/j.jhep.2022.04.005
Autor:
Edward J. Gane, Edwin DeJesus, Ewa Janczewska, Jacob George, Moises Diago, Mariliza Hendrique Da Silva, Henk Reesink, Igor Nikitin, Holger Hinrichsen, Stefan Bourgeois, Peter Ferenci, Umesh Shukla, Ronald Kalmeijer, Oliver Lenz, Bart Fevery, Chris Corbett, Maria Beumont, Wolfgang Jessner
Publikováno v:
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-13 (2017)
Abstract Background This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin (RBV) in a well-characterized population of HCV genotype 1 (GT1)-infect
Externí odkaz:
https://doaj.org/article/3cfa6244d4a94f6ba954c69bc057268c
Autor:
Olav Dalgard, Alain H. Litwin, Oren Shibolet, Jason Grebely, Ronald Nahass, Frederick L. Altice, Brian Conway, Edward J. Gane, Anne F. Luetkemeyer, Cheng-Yuan Peng, David Iser, Isaias Noel Gendrano, Michelle M. Kelly, Barbara A. Haber, Heather Platt, Amy Puenpatom
Publikováno v:
Journal of Addictive Diseases. :1-12
Background In people with chronic hepatitis C virus (HCV) infection, viral eradication is associated with improved health-related quality of life (HRQOL). Objective To assess changes in HRQOL among participants receiving opioid agonist therapy underg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::795cf120f9fca6524c7c848234ecf7ee
https://doi.org/10.1080/10550887.2022.2088978
https://doi.org/10.1080/10550887.2022.2088978
Publikováno v:
Frontiers in Transplantation. 1
The risk of spontaneous portal vein thrombosis (PVT) is increased in patients on the waiting list for liver transplantation and increases perioperative risks. A predictive PVT risk-index (PVT-RI) calculator has been proposed to determine the risk of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9869431423bbca44e59cc0dc0edf79e3
https://doi.org/10.3389/frtra.2022.1042684
https://doi.org/10.3389/frtra.2022.1042684